Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)

X
Trial Profile

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilovertamab vedotin (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms waveLINE-004
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 08 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2023 Updated results (At the data cutoff: April 26, 2023; n=98) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 15 Jun 2023 Early results (at the data cutoff: 16 Nov 2022, n=40) assessing efficacy and safety of zilovertamab vedotin in patients with diffuse large B-Cell lymphoma, presented at the 28th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top